Institution
Sunnybrook Health Sciences Centre
Healthcare•Toronto, Ontario, Canada•
About: Sunnybrook Health Sciences Centre is a healthcare organization based out in Toronto, Ontario, Canada. It is known for research contribution in the topics: Population & Breast cancer. The organization has 7689 authors who have published 15236 publications receiving 523019 citations. The organization is also known as: Sunnybrook.
Papers published on a yearly basis
Papers
More filters
••
TL;DR: The presence of distinct lymphatic channels in the human ciliary body is indicated, and that fluid and solutes flow at least partially through this system, leading to the discovery of a uveolymphatic pathway in the eye.
143 citations
••
Vanderbilt University Medical Center1, Vanderbilt University2, University of Manitoba3, Ohio State University4, Indiana University5, Trinity College, Dublin6, Northeastern University7, Tufts Medical Center8, University of British Columbia9, University of Edinburgh10, Stanford University11, Johns Hopkins University12, Watford General Hospital13, Sunnybrook Health Sciences Centre14, University of Toronto15, Federal University of Rio de Janeiro16, Pasteur Institute17, Monash University18, McGill University19, Utrecht University20, Monroe Carell Jr. Children's Hospital at Vanderbilt21
TL;DR: The epidemiology of delirium is reviewed, the current best practices for management of critically ill patients at risk forDelirium or experiencingdelirium are reviewed, recent advances in the understanding of delIRium are identified, as well as gaps in knowledge are identified.
Abstract: Delirium, a prevalent organ dysfunction in critically ill patients, is independently associated with increased morbidity. This last decade has witnessed an exponential growth in delirium research in hospitalized patients, including those critically ill, and this research has highlighted that delirium needs to be better understood mechanistically to help foster research that will ultimately lead to its prevention and treatment. In this invited, evidence-based paper, a multinational and interprofessional group of clinicians and researchers from within the fields of critical care medicine, psychiatry, pediatrics, anesthesiology, geriatrics, surgery, neurology, nursing, pharmacy, and the neurosciences sought to address five questions: (1) What is the current standard of care in managing ICU delirium? (2) What have been the major recent advances in delirium research and care? (3) What are the common delirium beliefs that have been challenged by recent trials? (4) What are the remaining areas of uncertainty in delirium research? (5) What are some of the top study areas/trials to be done in the next 10 years? Herein, we briefly review the epidemiology of delirium, the current best practices for management of critically ill patients at risk for delirium or experiencing delirium, identify recent advances in our understanding of delirium as well as gaps in knowledge, and discuss research opportunities and barriers to implementation, with the goal of promoting an integrated research agenda.
142 citations
••
TL;DR: The data suggest that the active, high affinity form of alpha 2 beta 1 binds calreticulin and that cal reticulin binding to the alpha 2 cytoplasmic domain may be required for stabilizing the high affinity state of this integrin.
142 citations
••
University of Brescia1, University Health Network2, Brigham Young University3, Intermountain Medical Center4, University of Pittsburgh5, Guy's and St Thomas' NHS Foundation Trust6, Katholieke Universiteit Leuven7, University of Michigan8, King Saud bin Abdulaziz University for Health Sciences9, University of Milano-Bicocca10, Vanderbilt University11, University of Chicago12, University of Toronto13, University of California, San Francisco14, Radboud University Nijmegen15, Sunnybrook Health Sciences Centre16, McMaster University17, St. Michael's GAA, Sligo18, Université libre de Bruxelles19, University of Paris20, Johns Hopkins University21
TL;DR: In this paper, the authors present areas of uncertainty concerning intensive care unit-acquired weakness (ICUAW) and identify areas for future research and identify methodological issues, including accounting for baseline status, handling of missing data, and inclusion of patient-centered outcome measures.
Abstract: We present areas of uncertainty concerning intensive care unit-acquired weakness (ICUAW) and identify areas for future research. Age, pre-ICU functional and cognitive state, concurrent illness, frailty, and health trajectories impact outcomes and should be assessed to stratify patients. In the ICU, early assessment of limb and diaphragm muscle strength and function using nonvolitional tests may be useful, but comparison with established methods of global and specific muscle strength and physical function and determination of their reliability and normal values would be important to advance these techniques. Serial measurements of limb and respiratory muscle strength, and systematic screening for dysphagia, would be helpful to clarify if and how weakness of these muscle groups is independently associated with outcome. ICUAW, delirium, and sedatives and analgesics may interact with each other, amplifying the effects of each individual factor. Reduced mobility in patients with hypoactive delirium needs investigations into dysfunction of central and peripheral nervous system motor pathways. Interventional nutritional studies should include muscle mass, strength, and physical function as outcomes, and prioritize elucidation of mechanisms. At follow-up, ICU survivors may suffer from prolonged muscle weakness and wasting and other physical impairments, as well as fatigue without demonstrable weakness on examination. Further studies should evaluate the prevalence and severity of fatigue in ICU survivors and define its association with psychiatric disorders, pain, cognitive impairment, and axonal loss. Finally, methodological issues, including accounting for baseline status, handling of missing data, and inclusion of patient-centered outcome measures should be addressed in future studies.
142 citations
••
University of Calgary1, McGill University2, University of Alberta3, University of British Columbia4, Montreal General Hospital5, University of Western Ontario6, Sunnybrook Health Sciences Centre7, Memorial University of Newfoundland8, Université du Québec à Trois-Rivières9, University of Saskatchewan10, University of Manitoba11, Jewish General Hospital12, Dalhousie University13, Laval University14, Simon Fraser University15, Ottawa Hospital Research Institute16, University of Ottawa17, University of Toronto18, Hôpital Maisonneuve-Rosemont19, Canadian Stroke Network20, University Health Network21, Queen Elizabeth II Health Sciences Centre22, Concordia University23, Lawson Health Research Institute24, Université de Sherbrooke25, Université de Montréal26, Saskatchewan Health27, St. Michael's Hospital28
TL;DR: The recent analyses that examined the association between angiotensin II receptor blockers (ARBs) and cancer were discussed and a recommendation was made to coordinate with pharmacists to improve antihypertensive medication adherence.
142 citations
Authors
Showing all 7765 results
Name | H-index | Papers | Citations |
---|---|---|---|
Gordon B. Mills | 187 | 1273 | 186451 |
David A. Bennett | 167 | 1142 | 109844 |
Bruce R. Rosen | 148 | 684 | 97507 |
Robert Tibshirani | 147 | 593 | 326580 |
Steven A. Narod | 134 | 970 | 84638 |
Peter Palese | 132 | 526 | 57882 |
Gideon Koren | 129 | 1994 | 81718 |
John B. Holcomb | 120 | 733 | 53760 |
Julie A. Schneider | 118 | 492 | 56843 |
Patrick Maisonneuve | 118 | 582 | 53363 |
Mitch Dowsett | 114 | 478 | 62453 |
Ian D. Graham | 113 | 700 | 87848 |
Peter C. Austin | 112 | 657 | 60156 |
Sandra E. Black | 104 | 681 | 51755 |
Michael B. Yaffe | 102 | 379 | 41663 |